SYS-CON MEDIA Authors: RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NanoViricides, Inc. - NNVC

NEW YORK, Feb. 11, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NanoViricides, Inc. ("NanoViricides" or the "Company")(NYSE MKT: NNVC).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether NanoViricides and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On Tuesday, February 11, 2014, a report was published on Seekingalpha.com website questioning the integrity of the company and its officers.  The article in part stated that, "NNVC shareholders seem unaware of [an] incriminating must-read document, written by a company insider and supporter, which outlines countless examples and allegations of NNVC managers Seymour and Diwan abusing shareholders and looting the company."

On this news, shares fell $1.42 per share to $3.00 or more than 32.13%, on February 11, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

SOURCE Pomerantz LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.